Disclosing conflicts of interest in clinical research

Views of institutional review boards, conflict of interest committees, and investigators

Kevin P. Weinfurt, Joëlle Y. Friedman, Michaela A. Dinan, Jennifer S. Allsbrook, Mark A. Hall, Jatinder K. Dhillon, Jeremy Sugarman

Research output: Contribution to journalArticle

Abstract

Strategies for disclosing investigators' financial interests to potential research participants have been adopted by many research institutions. However, little is known about how decisions are made regarding disclosures of financial interests to potential research participants, including what is disclosed and the rationale for making these determinations. We sought to understand the attitudes, beliefs, and practices of institutional review board chairs, conflict of interest committee chairs, and investigators regarding disclosure of financial interests to potential research participants. Several themes emerged, including general attitudes toward conflicts of interest, circumstances in which financial interests should be disclosed, rationales and benefits of disclosure, what should be disclosed, negative effects of and barriers to disclosure, and timing and presentation of disclosure. Respondents cited several rationales for disclosure, including enabling informed decision making, promoting trust in researchers and research institutions, and reducing legal liability. There was general agreement that disclosure should happen early in the consent process. Respondents disagreed about whether to disclose the amounts of particular financial interests. Clarifying the goals of disclosure and understanding how potential research participants use the information will be critical in efforts to ensure the integrity of clinical research and to protect the rights and interests of participants.

Original languageEnglish (US)
Pages (from-to)581-591
Number of pages11
JournalJournal of Law, Medicine and Ethics
Volume34
Issue number3
DOIs
StatePublished - Sep 2006

Fingerprint

Conflict of Interest
Research Ethics Committees
conflict of interest
Disclosure
Research Personnel
Research
Legal Liability
liability
integrity
Decision Making
decision making

ASJC Scopus subject areas

  • Law
  • Medicine (miscellaneous)

Cite this

Disclosing conflicts of interest in clinical research : Views of institutional review boards, conflict of interest committees, and investigators. / Weinfurt, Kevin P.; Friedman, Joëlle Y.; Dinan, Michaela A.; Allsbrook, Jennifer S.; Hall, Mark A.; Dhillon, Jatinder K.; Sugarman, Jeremy.

In: Journal of Law, Medicine and Ethics, Vol. 34, No. 3, 09.2006, p. 581-591.

Research output: Contribution to journalArticle

Weinfurt, Kevin P. ; Friedman, Joëlle Y. ; Dinan, Michaela A. ; Allsbrook, Jennifer S. ; Hall, Mark A. ; Dhillon, Jatinder K. ; Sugarman, Jeremy. / Disclosing conflicts of interest in clinical research : Views of institutional review boards, conflict of interest committees, and investigators. In: Journal of Law, Medicine and Ethics. 2006 ; Vol. 34, No. 3. pp. 581-591.
@article{aa71f013eb7547058922600e9d2deadd,
title = "Disclosing conflicts of interest in clinical research: Views of institutional review boards, conflict of interest committees, and investigators",
abstract = "Strategies for disclosing investigators' financial interests to potential research participants have been adopted by many research institutions. However, little is known about how decisions are made regarding disclosures of financial interests to potential research participants, including what is disclosed and the rationale for making these determinations. We sought to understand the attitudes, beliefs, and practices of institutional review board chairs, conflict of interest committee chairs, and investigators regarding disclosure of financial interests to potential research participants. Several themes emerged, including general attitudes toward conflicts of interest, circumstances in which financial interests should be disclosed, rationales and benefits of disclosure, what should be disclosed, negative effects of and barriers to disclosure, and timing and presentation of disclosure. Respondents cited several rationales for disclosure, including enabling informed decision making, promoting trust in researchers and research institutions, and reducing legal liability. There was general agreement that disclosure should happen early in the consent process. Respondents disagreed about whether to disclose the amounts of particular financial interests. Clarifying the goals of disclosure and understanding how potential research participants use the information will be critical in efforts to ensure the integrity of clinical research and to protect the rights and interests of participants.",
author = "Weinfurt, {Kevin P.} and Friedman, {Jo{\"e}lle Y.} and Dinan, {Michaela A.} and Allsbrook, {Jennifer S.} and Hall, {Mark A.} and Dhillon, {Jatinder K.} and Jeremy Sugarman",
year = "2006",
month = "9",
doi = "10.1111/j.1748-720X.2006.00072.x",
language = "English (US)",
volume = "34",
pages = "581--591",
journal = "Journal of Law, Medicine and Ethics",
issn = "1073-1105",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Disclosing conflicts of interest in clinical research

T2 - Views of institutional review boards, conflict of interest committees, and investigators

AU - Weinfurt, Kevin P.

AU - Friedman, Joëlle Y.

AU - Dinan, Michaela A.

AU - Allsbrook, Jennifer S.

AU - Hall, Mark A.

AU - Dhillon, Jatinder K.

AU - Sugarman, Jeremy

PY - 2006/9

Y1 - 2006/9

N2 - Strategies for disclosing investigators' financial interests to potential research participants have been adopted by many research institutions. However, little is known about how decisions are made regarding disclosures of financial interests to potential research participants, including what is disclosed and the rationale for making these determinations. We sought to understand the attitudes, beliefs, and practices of institutional review board chairs, conflict of interest committee chairs, and investigators regarding disclosure of financial interests to potential research participants. Several themes emerged, including general attitudes toward conflicts of interest, circumstances in which financial interests should be disclosed, rationales and benefits of disclosure, what should be disclosed, negative effects of and barriers to disclosure, and timing and presentation of disclosure. Respondents cited several rationales for disclosure, including enabling informed decision making, promoting trust in researchers and research institutions, and reducing legal liability. There was general agreement that disclosure should happen early in the consent process. Respondents disagreed about whether to disclose the amounts of particular financial interests. Clarifying the goals of disclosure and understanding how potential research participants use the information will be critical in efforts to ensure the integrity of clinical research and to protect the rights and interests of participants.

AB - Strategies for disclosing investigators' financial interests to potential research participants have been adopted by many research institutions. However, little is known about how decisions are made regarding disclosures of financial interests to potential research participants, including what is disclosed and the rationale for making these determinations. We sought to understand the attitudes, beliefs, and practices of institutional review board chairs, conflict of interest committee chairs, and investigators regarding disclosure of financial interests to potential research participants. Several themes emerged, including general attitudes toward conflicts of interest, circumstances in which financial interests should be disclosed, rationales and benefits of disclosure, what should be disclosed, negative effects of and barriers to disclosure, and timing and presentation of disclosure. Respondents cited several rationales for disclosure, including enabling informed decision making, promoting trust in researchers and research institutions, and reducing legal liability. There was general agreement that disclosure should happen early in the consent process. Respondents disagreed about whether to disclose the amounts of particular financial interests. Clarifying the goals of disclosure and understanding how potential research participants use the information will be critical in efforts to ensure the integrity of clinical research and to protect the rights and interests of participants.

UR - http://www.scopus.com/inward/record.url?scp=33749416589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749416589&partnerID=8YFLogxK

U2 - 10.1111/j.1748-720X.2006.00072.x

DO - 10.1111/j.1748-720X.2006.00072.x

M3 - Article

VL - 34

SP - 581

EP - 591

JO - Journal of Law, Medicine and Ethics

JF - Journal of Law, Medicine and Ethics

SN - 1073-1105

IS - 3

ER -